These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38654484)

  • 21. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
    Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
    Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
    Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
    Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction.
    Ferron GM; Preston RA; Noveck RJ; Pockros P; Mayer P; Getsy J; Turner M; Abell M; Paul J
    Clin Ther; 2001 Aug; 23(8):1180-92. PubMed ID: 11558857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic phenylalanine metabolism measured by the [13C]phenylalanine breath test.
    Kobayashi T; Kubota K; Imamura H; Hasegawa K; Inoue Y; Takayama T; Makuuchi M
    Eur J Clin Invest; 2001 Apr; 31(4):356-61. PubMed ID: 11298784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function.
    Sane R; Malhi V; Sutaria DS; Cho E; Twomey P; Craggs C; Wang J; Harris A; Musib L
    J Clin Pharmacol; 2022 Feb; 62(2):171-181. PubMed ID: 34402068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
    Abbas R; Chalon S; Leister C; El Gaaloul M; Sonnichsen D
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):123-32. PubMed ID: 23053269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit.
    Lin XB; Huang F; Tong L; Xia YZ; Wu JJ; Li J; Hu XG; Liang T; Liu XM; Zhong GP; Cai CJ; Chen X
    Int J Infect Dis; 2020 Apr; 93():345-352. PubMed ID: 32109625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The value of studying liver function reserve in hepatic carcinoma by 13C-methacetin breath test].
    Li HX; Wang JP; Yang Y; Zhang J; Feng QL
    Zhonghua Nei Ke Za Zhi; 2009 May; 48(5):383-7. PubMed ID: 19615155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
    Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
    Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant.
    Dayal S; Aluri J; Hall N; Filippov G; Moline M; Reyderman L; Landry I
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00758. PubMed ID: 33822479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of ondansetron in patients with hepatic insufficiency.
    Figg WD; Dukes GE; Pritchard JF; Hermann DJ; Lesesne HR; Carson SW; Songer SS; Powell JR; Hak LJ
    J Clin Pharmacol; 1996 Mar; 36(3):206-15. PubMed ID: 8690814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics.
    Li Y; Wang X; Liu L; Zhang C; Gomez D; Reyes J; Palmisano M; Zhou S
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):346-354. PubMed ID: 29746728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.
    Krauwinkel W; Noukens J; van Dijk J; Popa S; Ouatas T; de Vries M; Phung D; Gibbons J; Mordenti J; Mateva L
    J Clin Pharm Ther; 2017 Jun; 42(3):268-275. PubMed ID: 28251667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 13C-phenylalanine and 13C-methacetin breath test to evaluate functional capacity of hepatocyte in chronic liver disease.
    Lara Baruque S; Razquin M; Jimenez I; Vazquez A; Gisbert JP; Pajares JM
    Dig Liver Dis; 2000 Apr; 32(3):226-32. PubMed ID: 10975773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and safety of nifedipine GITS/candesartan fixed-dose combination in subjects with hepatic impairment
.
    Liu Y; Boettcher MF; Schmidt A; Unger S; Halabi A; Brendel E; Blode H
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):246-255. PubMed ID: 28025965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
    Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
    Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.
    Zahir H; Greenberg J; Hsu C; Marbury TC; Lasseter KC; Xu LA; Tap WD; Healey JH; Stacchiotti S; LaCreta F
    J Clin Pharmacol; 2022 Aug; 62(8):992-1005. PubMed ID: 35247274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
    Mogalian E; Brainard DM; Osinusi A; Moorehead L; Murray B; Ling KHJ; Perry R; Curtis C; Lawitz E; Lasseter K; Marbury T; Mathias A
    Clin Pharmacokinet; 2018 Nov; 57(11):1449-1457. PubMed ID: 29520729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.